Rosuvastatin significantly improves lipid parameters and ability to achieve low-density lipoprotein cholesterol goals compared with pravastatin

Barter, Philip J.; Shepherd, James; Brown, W. Virgil; Bays, Harold; Southworth, Harry; Strutt, Kristina

doi:10.1046/j.1443-9506.2003.01788.x

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both rosuvastatin doses were also associated with a significantly greater achievement of the aggressive LDL-C goal of <100 mg/dL (<2.59 mmol/L) in patients with CHD or CHD risk equivalents. In analysis of pooled data from the two trials comparing rosuvastatin with simvastatin and pravastatin, both rosuvastatin 5 mg (n = 240) and rosuvastatin 10 mg (n = 226) produced significantly greater reductions in LDL-C, compared with simvastatin 20 mg (n = 249) (41 and 48% vs. 36%, both P < 0.001) and pravastatin 20 mg (n = 252) (41 and 48% vs. 27%, both P < 0.001) (3,23). Rosuvastatin 10 mg increased HDL-C significantly more than simvastatin 20 mg (9 vs. 6%, P < 0.05) or pravastatin 20 mg (9 vs. 6%, P < 0.05).…”

Section: Pooled Data Analysesmentioning

confidence: 98%

Rosuvastatin: A Highly Effective New HMG‐CoA Reductase Inhibitor

Olsson

McTaggart

Raza

2002

Cardiovascular Drug Reviews

186

113

View full text Add to dashboard Cite

Rosuvastatin, a new statin, has been shown to possess a number of advantageous pharmacological properties, including enhanced HMG-CoA reductase binding characteristics, relative hydrophilicity, and selective uptake into/activity in hepatic cells. Cytochrome P450 (CYP) metabolism of rosuvastatin appears to be minimal and is principally mediated by the 2C9 enzyme, with little involvement of 3A4; this finding is consistent with the absence of clinically significant pharmacokinetic drug-drug interactions between rosuvastatin and other drugs known to inhibit CYP enzymes. Dose-ranging studies in hypercholesterolemic patients demonstrated dose-dependent effects in reducing low-density lipoprotein cholesterol (LDL-C) (up to 63%), total cholesterol, and apolipoprotein (apo) B across a 1-to 40-mg dose range and a significant 8.4% additional reduction in LDL-C, compared with atorvastatin, across the dose ranges of the two agents. Rosuvastatin has also been shown to be highly effective in reducing LDL-C, increasing high-density lipoprotein cholesterol (HDL-C), and producing favorable modifications of other elements of the atherogenic lipid profile in a wide range of dyslipidemic patients. In patients with mild to moderate hypercholesterolemia, rosuvastatin has been shown to produce large decreases in LDL-C at starting doses, thus reducing the need for subsequent dose titration, and to allow greater percentages of patients to attain lipid goals, compared with available statins. The substantial LDL-C reductions and improvements in other lipid measures with rosuvastatin treatment should facilitate achievement of lipid goals and reduce the requirement for combination therapy in patients with severe hypercholesterolemia. In addition, rosuvastatin's effects in reducing triglycerides, triglyceride-containing lipoproteins, non-HDL-C, and LDL-C and increasing HDL-C in patients with mixed dyslipidemia or elevated triglycerides should be of considerable value in enabling achievement of LDL-C 303 and non-HDL-C goals in the numerous patients with combined dyslipidemias or metabolic syndrome who require lipid-lowering therapy. Rosuvastatin is well tolerated alone, and in combination with fenofibrate, extended-release niacin, and cholestyramine, and has a safety profile similar to that of currently marketed statins. A large, long-term clinical trials program is under way to investigate the effects of rosuvastatin on atherosclerosis and cardiovascular morbidity and mortality.

show abstract

Section: Pooled Data Analysesmentioning

confidence: 98%

Rosuvastatin: A Highly Effective New HMG‐CoA Reductase Inhibitor

Olsson

McTaggart

Raza

2002

Cardiovascular Drug Reviews

186

113

View full text Add to dashboard Cite

show abstract

“…Statins can also increase the concentration of HDL‐C, especially when the baseline level is low; this increase is generally in the 5–10% range, although rosuvastatin has been shown to raise HDL‐C by as much as 18% in patients with hypertriglyceridaemia 113 . Indeed, HDL‐C‐raising efficacy varies among statins, as indicated by pooled analyses from several short‐term trials comparing rosuvastatin 10 mg with pravastatin 20 mg (9.1% vs 6.1%, p<0.05), simvastatin 20 mg (9.1% vs 6.2%, p<0.05) or atorvastatin 10 mg (8.9% vs 5.5%, p<0.01, respectively) 114–116 . However, the assertion that statin‐induced increases in HDL‐C translate into clinical benefit remains to be proven.…”

Section: Interventions and Guidelines For Raising Hdl‐cmentioning

confidence: 99%

High Density Lipoprotein: Guardian of the Vascular System?

Packard

Nunn

2002

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYThe role of low‐density lipoprotein in the development of coronary heart disease (CHD) is well recognised. There is also growing evidence that high‐density lipoprotein cholesterol (HDL‐C) is a powerful inverse predictor for premature CHD and that maintaining a high HDL‐C level may guard against atherosclerosis. Patients with low HDL‐C levels often also have central obesity, insulin resistance and other features of the metabolic syndrome. This syndrome is both increasingly common and strongly implicated in the growing worldwide epidemic of type 2 diabetes. HDL‐C may be increased by lifestyle changes, e.g. weight loss, physical activity and smoking cessation. Pharmacological agents such as fibrates, niacin and statins have also been shown significantly to elevate HDL‐C. Although current guidelines are beginning to recognise the protective role of HDL‐C level in preventing coronary events, HDL‐C should be adopted soon as a target for intervention in its own right.

show abstract

Apolipoproteins: the new prognostic indicator?

Packard

2003

European Heart Journal Supplements

View full text Add to dashboard Cite

Rosuvastatin significantly improves lipid parameters and ability to achieve low-density lipoprotein cholesterol goals compared with pravastatin

Cited by 4 publications

References 0 publications

Rosuvastatin: A Highly Effective New HMG‐CoA Reductase Inhibitor

Rosuvastatin: A Highly Effective New HMG‐CoA Reductase Inhibitor

High Density Lipoprotein: Guardian of the Vascular System?

Apolipoproteins: the new prognostic indicator?

Contact Info

Product

Resources

About